Protara Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Protara Therapeutics, Inc.
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
- Other Names / Subsidiaries
- Proteon Therapeutics, Inc.
- ArTara Therapeutics, Inc.